R&D, Setbacks, Special

The top 10 pipeline blowups, setbacks and snafus for H2 2018

Startups, Venture

James Wilson turns to old mentor for gene therapy startup's star-studded $115M launch round

FDA, Regulatory

Tropical disease PRV fix didn’t stop Novartis from winning another
More news caret

calendar Protocols

Quick hits from around the biopharma web

Feb 15

GW Pharma cannabinoid to be tested for Alzheimer's agitation; Acorda revenue plummets as generics eviscerate its franchise

Feb 14

Merck goes in deeper with Keytruda/Lynparza combo; PureTech unveils stem cell therapy startup

Feb 13

Charles River drops $510M to bag non-clinical CRO; Magpie raises $14.8M Series B to modernize traditional Chinese meds

Feb 12

China vows to continue speeding up drug approvals, expand tax cuts; Sorrento/Yuhan JV receives $40M financing

More Protocols caret

person Peer Review

Weekly biopharma careers news report

Feb 15

J&J R&D vet Peter Tummino joins the Big Pharma exodus, leaping to Nimbus as CSO; Cadent taps Jodie Morrison for CEO

Feb 8

MorphoSys taps Bavencio lead for US operations; Two top FDA officials move to industry

Feb 1

Richard Pascoe takes the helm at Histogen; Lonza COO steps up at CEO Richard Ridinger retires

Jan 30

Path to the top: What kind of experience does it take to get tapped for the helm of a biotech?

More peer review caret

Dollar Premium

The $100M biotech club: Who's in, and what’s it take to join the top-performing group of biopharmas?

The high rollers: The top 20 blockbuster biopharma deals of the past decade

Top 20 biotech deals: 2019 dealmaking gets off to a roaring start, building on a record amount for '18

AstraZeneca CEO Soriot is overseeing a top exec team overhaul in move to integrate MedImmune in a sweeping restructuring

Path to the top: What kind of experience does it take to get tapped for the helm of a biotech?

By the numbers for 2018: The top 100 venture players in biotech — and who's been paying the piper in cancer R&D?

Scoop: GSK’s venture team at SR One in talks to spin off from its big pharma founder, now under new R&D management

Celgene's top 20 upfront hits: Just how generous was Celgene in dealmaking? Let's review the records

So what did we learn from JPMorgan week? Buckle up, it’s going to be a bumpy ride

bullhorn Bioregnum

The view from John Carroll

Jan 29

As Pfizer kills failed PhIII programs for Bavencio, where do they go from here in R&D?

Jan 25

The antibiotics R&D effort is broken. Here's one market solution that might fix it

Jan 17

Short seller Citron draws fresh blood going after another biotech scalp — but can it still cut that deep?

Jan 16

Allergan and its Mohawk allies pitch their sovereign immunity case to SCOTUS. And the timing couldn't be worse

More opinion caret

twitter Marco

Hot BioTwitter bot - last updated ago

arrow-thick Most Viral

timer Latest

OncLive

PARP Inhibitors Hold Promise in mCRPC and Biallelic DNA Repair Gene Defects

CMS

Proposed Decision Memo for Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers (CAG-00451N)

MIT Technology Review

A cell-killing strategy to slow aging passed its first test this year

New York Times

The Instant, Custom, Connected Future of Medical Devices

WIRED

How Measles Hacks the Body-and Harms Its Victims for Years

NEJM

Rogues and Regulation of Germline Editing

OncLive

Dr. Brahmer on Immunotherapy Beyond PD-1/L1 in NSCLC

bioRxiv

High-Fidelity Nanopore Sequencing of Ultra-Short DNA Sequences

KevinMD.com

How should physicians hear back about their diagnostic errors?

NPR.org

'Not Letting It Define Us' - Walking The Runway With Metastatic Breast Cancer

fire Hot This Week

1

STAT

Gilead Sciences posts negative results in late-stage NASH trial

2

PR Newswire

Alvogen and Lotus Launch the First Generic Equivalent to Revlimid™ Capsules in Selected European Countries

3

STAT

Depression drug related to ketamine wins endorsement of advisory panel

4

ASCO

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study

5

MedScape

'Leading the Charge' on Racism, Sexism, Activism in Medicine

6

STAT

A big PBM wants drug makers to agree to rebate demands- STAT

7

ASCO

NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02

8

STAT

Medicare would provide national coverage for CAR-T under new proposal

9

STAT

How can we make the J.P. Morgan Healthcare Conference better? - STAT

10

Evaluate.com

Asco-GU - Nektar gets that sinking feeling again

Contact Endpoints News

You can also contact John Carroll, Editor at john@endpointsnews.com

← Go back
Thank you for staying with us. It's great to have you on board!
Aww, shucks. Perhaps you can tell us what we could do to make you interested in subscribing?
← Go back